Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. (Q38619950)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515897%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515897%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

0 references

0 references

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515897%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

A Hart

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515897%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

P De Cruz

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515897%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

30 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515897%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515897%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515897%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

30-51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515897%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515897%20AND%20SRC:MED&resulttype=core&format=json

Adverse effects of biologics: a network meta-analysis and Cochrane overview

28 February 2020

cites work

1 reference

Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease

21 January 2018

1 reference

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms

21 January 2018

1 reference

Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis

21 January 2018

1 reference

Review article: loss of response to anti-TNF treatments in Crohn's disease

21 January 2018

1 reference

Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review

21 January 2018

1 reference

Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.

21 January 2018

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.

21 January 2018

1 reference

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

21 January 2018

1 reference

Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis

21 January 2018

1 reference

Phenotypic features of Crohn's disease associated with failure of medical treatment.

21 January 2018

1 reference

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

21 January 2018

1 reference

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials

21 January 2018

1 reference

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

21 January 2018

1 reference

Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

21 January 2018

1 reference

Clinical pharmacokinetics of therapeutic monoclonal antibodies

21 January 2018

1 reference

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease

21 January 2018

1 reference

High-dose infliximab for treatment of pediatric ulcerative colitis: a survey of clinical practice

21 January 2018

1 reference

Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients.

21 January 2018

1 reference

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.

21 January 2018

1 reference

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data

21 January 2018

1 reference

Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study

21 January 2018

1 reference

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

21 January 2018

1 reference

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

21 January 2018

1 reference

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis

21 January 2018

1 reference

Adalimumab induces deep remission in patients with Crohn's disease.

21 January 2018

1 reference

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.

21 January 2018

1 reference

Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse

21 January 2018

1 reference

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

21 January 2018

1 reference

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

21 January 2018

1 reference

Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial

21 January 2018

1 reference

Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative

21 January 2018

1 reference

Fecal lactoferrin: a new parameter to monitor infliximab therapy.

21 January 2018

1 reference

C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease.

21 January 2018

1 reference

Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort

21 January 2018

1 reference

Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease

21 January 2018

1 reference

ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease

21 January 2018

1 reference

Serological antibodies in inflammatory bowel disease: a systematic review.

21 January 2018

1 reference

Endoscopic and medical management of fibrostenotic Crohn's disease

21 January 2018

1 reference

Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.

21 January 2018

1 reference

Predicting response to Anti-TNF Agents for the treatment of crohn's disease

21 January 2018

1 reference

Lymphotoxin alpha gene in Crohnʼs disease patients: absence of implication in the response to infliximab in a large cohort study

21 January 2018

1 reference

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.

21 January 2018

1 reference

NOD2/CARD15 does not influence response to infliximab in Crohn's disease

21 January 2018

1 reference

IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab

21 January 2018

1 reference

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.

21 January 2018

1 reference

Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors

21 January 2018

1 reference

Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis

21 January 2018

1 reference

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâ s disease after failure of two other anti-TNF antibodies

21 January 2018

1 reference

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

21 January 2018

1 reference

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

21 January 2018

1 reference

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

21 January 2018

1 reference

Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys.

21 January 2018

1 reference

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial

21 January 2018

1 reference

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

Optimizing anti-TNF treatments in inflammatory bowel disease

21 January 2018

1 reference

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

21 January 2018

1 reference

Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort

21 January 2018

1 reference

Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center

21 January 2018

1 reference

Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.

21 January 2018

1 reference

Predictors of response to infliximab in patients with Crohn's disease

21 January 2018

1 reference

Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.

21 January 2018

1 reference

Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study

21 January 2018

1 reference

Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics

21 January 2018

1 reference

Infliximab treatment for symptomatic Crohn's disease strictures

21 January 2018

1 reference

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis

21 January 2018

1 reference

Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

21 January 2018

1 reference

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

21 January 2018

1 reference

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

21 January 2018

1 reference

Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease

21 January 2018

1 reference

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study

21 January 2018

1 reference

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.

21 January 2018

1 reference

Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.

21 January 2018

1 reference

Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease

21 January 2018

1 reference

Pharmacogenetics of Crohn's disease

21 January 2018

1 reference

Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab

21 January 2018

1 reference

Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients.

21 January 2018

1 reference

IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab.

21 January 2018

1 reference

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

21 January 2018

1 reference

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy

21 January 2018

1 reference

Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.

21 January 2018

1 reference

Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab

21 January 2018

1 reference

Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohnʼs disease: a subanalysis of the ACCENT I study

21 January 2018

1 reference

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials

21 January 2018

1 reference

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

21 January 2018

1 reference

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.13445

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515897%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515897%20AND%20SRC:MED&resulttype=core&format=json